eligibility_summary
Eligibility: Adults (≥18) with relapsed/refractory NHL after ≥1 line, planned CD19 CAR‑T, ECOG 0–1, adequate organs (ANC ≥1.5k, platelets ≥100k, bili normal or Gilbert’s, AST/ALT ≤3×ULN, Cr ≤1.5×ULN or GFR ≥40 [≥30 if supported]), accessible lesion and consent to biopsies. Controlled HIV/HBV/HCV allowed, CNS mets allowed if no urgent CNS therapy. Contraception required. Exclude: noncompliance, pregnancy, breastfeeding must stop during 64Cu‑GRIP B, hypersensitivity to 64Cu‑GRIP B.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: 64Cu-GRIP B, an IV PET radiopharmaceutical (64Cu-labeled peptide that binds granzyme B), PET imaging, and optional biopsy. Mechanism of action: GRIP B selectively binds extracellular granzyme B secreted by activated cytotoxic immune cells, the 64Cu label enables whole-body PET visualization. Purpose: to image immune cytolytic activity in the tumor microenvironment before/after CD19-directed CAR-T therapy in relapsed/refractory NHL, to assess feasibility, uptake patterns vs conventional imaging, and safety. Targets: granzyme B (effector protease) indicating activity of CD19 CAR-T cells, CD8+ T cells, and NK cells, pathway—perforin/granzyme-mediated tumor cell apoptosis.